<DOC>
	<DOCNO>NCT00002577</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . PURPOSE : Phase I/II trial study effectiveness radiation therapy treat patient non-small cell lung cancer surgically remove .</brief_summary>
	<brief_title>Radiation Therapy Treating Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess treatment related morbidity associate escalate dos 3-dimensional conformal radiotherapy ( 3D-CRT ) patient locally advance , inoperable , non-small cell lung cancer . II . Determine maximum tolerate dose 3D-CRT patient . III . Evaluate morbidity associate high dose 3D-CRT carcinoma lung . OUTLINE : This dose escalation study . Patients stratify percentage total lung volume ( TLV ) receive great 20 Gy radiation ( le 25 % vs 25 % le 37 % v least 37 % ) . As 7/1/1999 , third stratum close accrual . Patients receive 3-dimensional conformal radiotherapy ( 3D-CRT ) 5 day week either 6-7 week , 7-8 week , 9-10 week ( depend cohort ) . Within TLV stratum , cohorts 15-36 patient receive escalate dos 3D-CRT maximum tolerate dose ( MTD ) determine . The MTD define dose less 15 % patient experience dose limit toxicity . Patients follow every 3 month 1 year , every 4 month 1 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 15-36 patient per cohort accrue study within 1 year . As 7/1/1999 , third stratum close accrual .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove nonsmall cell lung cancer follow histologic type : Squamous cell carcinoma Adenocarcinoma Undifferentiated large cell carcinoma Not otherwise specify ( i.e. , diagnosis cytology alone ) Unresectable stage I , II , III disease Measurable lesion Primary nodal lesion encompassable within radiotherapy field No positive supraclavicular lymph node ( stage N3 ) No massive atelectasis No complete remission treat chemotherapy Prior cisplatin , vinblastine , etoposide , paclitaxel , carboplatin , vinorelbine allow All chemotherapy deliver within 4 month entry No pleural effusion positive cytology Other pleural effusion eligible following requirement : Present prior mediastinoscopy exploratory thoracotomy Transudate cytologically negative 2 separate thoracenteses OR Present mediastinoscopy exploratory thoracotomy Either transudate exudate negative cytology thoracentesis OR Present CT chest xray Too small tap CT ultrasound guidance Ineligible treatment RTOG phase III study PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No second malignancy within past 5 year except nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic response modifier therapy Chemotherapy : See Disease Characteristics At least 6 month since prior bleomycin , mitomycin , doxorubicin , cyclophosphamide No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior thoracic irradiation Surgery : Ineligible definitive surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
</DOC>